Last reviewed · How we verify
Zegalogue (DASIGLUCAGON)
Zegalogue works by stimulating the release of glucose from stored energy sources in the body.
Zegalogue (DASIGLUCAGON) is a small molecule antihypoglycemic agent developed by Zealand Pharma, targeting the glucagon receptor. It was FDA-approved in 2021 for the treatment of hypoglycemia due to diabetes mellitus. Zegalogue is a patented medication with no generic manufacturers available. Key safety considerations include its potential to cause nausea, vomiting, and headache. As a glucagon receptor agonist, it works by stimulating the release of glucose from stored energy sources in the body.
At a glance
| Generic name | DASIGLUCAGON |
|---|---|
| Sponsor | Zealand Pharma |
| Drug class | Antihypoglycemic Agent [EPC] |
| Target | Glucagon receptor |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2021 |
Mechanism of action
Dasiglucagon is glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.
Approved indications
- Hypoglycemia due to diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Headache
- Diarrhea
- Injection site pain
- Hypertension
- Hypotension
- Bradycardia
- Presyncope
- Palpitations
- Orthostatic intolerance
Key clinical trials
- Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism (PHASE3)
- Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents (PHASE1)
- A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D (PHASE3)
- Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism (PHASE2,PHASE3)
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (PHASE2)
- A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism (PHASE3)
- Micro Glucagon During Exercise in Type 1 Diabetes (EARLY_PHASE1)
- A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zegalogue CI brief — competitive landscape report
- Zegalogue updates RSS · CI watch RSS
- Zealand Pharma portfolio CI